DOJ announced that Veloxis Pharmaceuticals agreed to pay more than $46 million to resolve criminal and civil allegations tied to kickback schemes involving prescriptions for a transplant drug. The resolution centers on alleged unlawful payments and federal healthcare program implications, with DOJ framing the case around program integrity and patient safety. The case underscores continued enforcement against pharmaceutical marketing practices that may influence prescribing.
